All posts by Genetic Signatures

Genetic Signatures CSO Presenting at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Vienna, Austria

By | Latest News | No Comments

Molecular diagnostics (MDx) company Genetic Signatures’ Chief Scientific Officer, Dr Doug Millar has been selected to present at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), to be held 22-25 April 2017 in Vienna, Austria.

The presentation will highlight Genetic Signatures’ proprietary 3base™ technology and upcoming EasyScreenTM detection kits, including the EasyScreen™ Flavivirus and Alphavirus Detection Kit. This Detection kit is designed to detect 8 of the most common Flavivirus and Alphavirus infections in the world.

Dr Millar’s oral presentation will be in Hall C Session: New Approaches in Molecular Diagnostics Virology on the 23rd April 2017 at 2.30pm (CEST).

Visit Genetic Signatures at Booth #137 at ECCMID 2017 for more information.

Click here to visit ECCMID 2017


About Flavivirus: The Flaviviridae are a family of positive, single-stranded, enveloped RNA viruses. They are found in arthropods, (primarily ticks and mosquitoes), and can occasionally infect humans.

Members of this family belong to a single genus, Flavivirus, and cause widespread morbidity and mortality throughout the world. Some of the mosquitoes-transmitted viruses include: Yellow FeverDengue FeverJapanese encephalitisWest Nile viruses and Zika Virus1.

About ECCMID: The 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is one of the largest European Infectious diseases meetings. The congress provides a forum for the world’s leading experts who come together to discuss the latest developments in diseases, infection control and clinical microbiology.

  1. The CDC website: Viral Hemorrhagic Fevers (VHFs) https://www.cdc.gov/vhf/virus-families/flaviviridae.html

Genetic Signatures’ CEO & CSO presenting at Gene Target Solutions Symposium, Sydney Australia.

By | Latest News | No Comments

Molecular diagnostics (MDx) company Genetic Signatures’ CEO Dr John Melki and CSO Dr Doug Miller will present at the inaugural Gene Target Solutions Symposium: qPCR, Past Present and Future on the 13-14th March 2017 in Sydney, Australia.

CEO Dr Melki’s presentation is entitled “History of 3base™ technology and its application in molecular diagnostics.” The presentation will highlight the background of Genetic Signatures novel technology and its utilisation in the field of Molecular Diagnostics.

The second presentation by CSO Dr Miller is entitled, “Application of 3base™ technology to the detection of diverse families of both DNA and RNA viruses.” Dr Miller will discuss the molecular applications of Genetic Signatures 3base™ technology for species identification of infectious pathogens.

Meet Genetic Signatures CEO and CSO at qPCR Symposium Australia for more information.

Click here to visit the qPCR Symposium Australia website 


About Gene Target Solutions Symposium: qPCR Symposium Australia is a conference featuring renowned International and Australian speakers. This inaugural symposium hosted by Australian owned company Gene Target Solutions, is the first and only Australian event purely dedicated to qPCR.

Genetic Signatures exhibiting at the 24th International Molecular Medicine TRI-Conference (MMTC)

By | Latest News | No Comments

Molecular diagnostics (MDx) company Genetic Signatures Ltd will exhibit at the 24th International Molecular Medicine TRI-Conference (MMTC) in San Francisco, CA on 20th–22nd February 2017.

Genetic Signatures will be exhibiting their novel products for the detection of infectious diseases, including reagents for diagnosing bacterial, viral and protozoan causes of gastroenteritis, respiratory infections and Sexually Transmitted Infections. These reagents are based on the company’s proprietary 3base™ technology, allowing for more efficient detection of infectious microorganisms.

Visit Genetic Signatures at Booth 09 at MMTC 2017 for more information.

Click here to visit the MMTC website. 


 

About MMTC 2017: MMTC also known as Tri-Con is an annual precision medicine event attracting over 3,500 senior level scientists and executives focused in the areas of Molecular Medicine specifically on Discovery, Genomics, Diagnostics and Informatics.

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3baseTM. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreenTM brand. Genetic Signatures’ proprietary MDx 3baseTM platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Genetic Signatures exhibiting at the 16th Asia- Pacific Congress of Clinical Microbiology and Infection (APCCMI)

By | Latest News | No Comments

Genetic Signatures will exhibit at the 16th Asia-Pacific Congress of Clinical Microbiology and Infection (APCCMI) in Melbourne, Australia on 30 November – 3 December 2016.

Genetic Signatures will be exhibiting their EasyScreen products for the detection of infectious diseases, including kits for diagnosing bacterial, viral and protozoan causes of gastroenteritis direct from faeces, and the causes of respiratory infection from swabs in Viral Transport Media (VTM).

Visit Genetic Signatures at Booth 01 at APCCMI 2016 for more information.

Click here to visit the APCCMI website


About APCCMI: APPCMI is an important meeting on clinical microbiology and infectious diseases offering a unique opportunity for clinicians, scientists, researchers, pharmacists and other healthcare professionals working in the Asia Pacific region to meet international experts from various parts of the world. The programme will include presentations on antibiotic stewardship and antimicrobial resistance, infection prevention and control, public health, mycobacterial diseases, virology including HIV, hepatology, parasitology, bacteriology including diagnostics and vaccines.

 

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™. Founded in 2001 by the late Dr Geoffrey Grigg, the former Chief of Molecular Biology at CSIRO, Genetic Signatures has released a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. MDx is a modern technique increasingly used by hospitals and pathology laboratories to detect specific sequences of the genome, the DNA or RNA that define an organism. Genetic Signatures’ proprietary MDx 3Base™ platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening. As the spread of infectious diseases around the world continues to grow, the Company plans to launch additional products for the detection of pathogens associated with MRSA, sexual health infections, tuberculosis, meningitis and, antibiotic resistance.

Preliminary Results of EasyScreen™ STI Detection Kit Clinical Validation Trial

By | ASX Announcements, Latest News | No Comments
  • Results show 100% concordance with traditional and confirmatory methods
  • EasyScreen Sexually Transmitted Infection (STI) Detection Kit offers testing for an increased number of disease targets compared to traditional workflows
  • Preliminary Results to be presented at the NRL molecular diagnostics workshop, which is an annual meeting of opinion leaders from pathology testing laboratories
  • Further progress made toward market release of the EasyScreen™ Sexually Transmitted Infection (STI) Detection Kit

Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) is pleased to announce that the preliminary results of a clinical validation trial of the Company’s EasyScreen™ Sexually Transmitted Infection (STI) Detection Kit will be presented today at the NRL Molecular Diagnostics Workshop in Melbourne, Australia. The presentation, entitled “Evaluation of a new 3Base™ Assay for Screening of Sexually Transmitted Infections” will be given by Dr. Damien Stark of St. Vincent’s Hospital (SydPath).

The NRL Molecular Diagnostics Workshop is a leading forum for scientists, regulators, test kit manufacturers and clinicians to meet and discuss current issues and new technologies occurring in the world of molecular pathology for infectious diseases.

Sexually Transmitted Infections (STIs) have a significant impact on sexual and reproductive health with the World Health Organisation (WHO) reporting that more than 1 million STIs are contracted on a daily basis[1]. The EasyScreen™ STI Detection Kit was designed to cater for the large addressable STI testing market, estimated to be US $550M in 2017[2].

The clinical validation results have shown that the EasyScreen™ STI Detection Kit allowed the simultaneous identification of 12 of the most significant and commonly encountered STIs with 100% concordance with traditional and confirmatory methods. It was shown the assay offered improved accuracy and sensitivity (true positive detection), and additional STI pathogens were identified over existing testing techniques.

We are very pleased with these results.” said John Melki PhD, CEO of Genetic Signatures. “The rate of STI co-infection is high, and this trial showed that 25.9% of the patient samples had mixed infections (≥2 pathogens detected). These high rates of co- and mixed infections require an assay that can simultaneously screen for a large number of disease targets. As the assay performed so well in this trial we feel confident we have achieved this aim and can now progress toward regulatory approval and market release.”

SydPath is a fully accredited registered pathology laboratory service located within the St Vincent’s Hospital Campus, and an existing customer of the company’s EasyScreen™ products that screen for a wide range of infectious agents including viral, bacterial and protozoan agents.

SydPath Senior Hospital Scientist Dr Damien Stark commented on the results saying that: “The EasyScreen™ STI Detection Kit allows simultaneous detection of more STIs than our current methodologies and algorithms. The Genetic Signatures STI test could be easily integrated into our current EasyScreen™ workflow and would allow us to consolidate our STI screening methods. We look forward to completing the study and publishing these results.”

Click here to download the full press release

About Sexually Transmitted Infections: The WHO has reported that each year, there are an estimated 357 million new infections with one of four STIs: chlamydia, gonorrhoea, syphilis and trichomoniasis. More than 500 million people are estimated to have genital infection with herpes simplex virus (HSV) and more than 290 million women have a human papillomavirus (HPV) infection. The majority of STIs have no symptoms or only mild symptoms that may not be recognized as an STI. STIs such as HSV type 2 and syphilis can increase the risk of HIV acquisition. Over 900,000 pregnant women were infected with syphilis resulting in approximately 350,000 adverse birth outcomes including stillbirth in 2012. In some cases, STIs can have serious reproductive health consequences beyond the immediate impact of the infection itself (e.g, infertility or mother-to-child transmission)[1].

About the EasyScreen™ STI Detection Kit: The STIs detected by the EasyScreen™ STI Detection Kit are Chlamydia trachomatis (Chlamydia), Neisseria gonorrhoeae (Gonorrhoea), Lymphogranuloma venereum (LGV), Mycoplasma Genitalium, Trichomonas vaginalis,  Ureaplasma spp. Candida spp. (Thrush), Mycoplasma hominis, Streptococcus agalactiae (Group B Streptococcus), Treponema pallidum (Syphilis), Herpes Simplex Virus 1 (HSV1) and Herpes Simplex Virus 2 (HSV2).


 

[1] http://www.who.int/mediacentre/factsheets/fs110/en/

[2] Source: World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) Kalorama Information, Published: 1/9/2013, page 168

Genetic Signatures CEO presentation at the 7th Annual Australian Microcap Investment Conference

By | Latest News | No Comments
  • Genetic Signatures to present its global growth strategy for the development and supply of world leading molecular diagnostic products 
  • The largest conference in Australia focused on microcap investment opportunities 
  • Presentations from the CEOs of 24 of Australia’s leading emerging companies 

Molecular Diagnostic (MDx) company Genetic Signatures (ASX: GSS) is pleased to release a copy of the presentation that Chief Executive Officer, John Melki, PhD., will deliver today at the 7th Annual Australian Microcap Investment Conference.

Dr Melki will present on Genetic Signatures’ commercialisation progress, financial results, and achievements to date. The presentation will also detail the Company’s global growth strategy for the sale of world leading solutions for the rapidly growing infectious disease detection market.

Dr Melki said: “2016 was a successful year for Genetic Signatures with record sales revenues and completion of a $15M capital raising. I am looking forward to updating the microcap conference attendees on our progress over the last 12 months and how we are driving shareholder value by accelerating the Company’s growth on a number of fronts.”

Click here to Download the Full Press Release & Presentation